- InMed Pharmaceuticals (INM) said on Friday it received a Nasdaq notice after reporting shareholders’ equity of $1.08M, below the $2.5M minimum required for continued listing.
- The company has 45 days to submit a compliance plan. It expects its planned merger with Mentari Therapeutics and related financing to restore compliance.
